RestorLife Med review

RestorLife Med gets right what many telehealth sites miss: a named, board-certified founder in Dr. Michael Wasef, a LegitScript seal on the site, a published business address, coverage in all 50 states, and sermorelin published at $149 a month with the consultation, monthly check-ins, dose adjustments, unlimited messaging and shipping stated as included. Two things to be precise about. The sermorelin page itself calls its pricing introductory and subject to change. And sermorelin is not the flagship of a peptide line — it is the entire peptide line, sold as a complement to a hormone-therapy and GLP-1 practice, and there is no NAD⁺, glutathione or repair peptide anywhere on the site.

RestorLife Med is a physician-guided telehealth practice founded by Dr. Michael Wasef, MD, described as board-certified in internal medicine and licensed in all 50 states. Its catalog is organized in three bands: hormone therapy (estradiol as patch, gel or oral tablet, and oral progesterone), anti-aging (sermorelin, positioned as a natural complement to hormone therapy), and weight loss (compounded semaglutide and tirzepatide in full and microdose entry protocols, compounded with B12 and including a free quarterly blood test on the GLP-1 protocols). Medication is stated as sourced from FDA-regulated, state-licensed US compounding pharmacies, and every patient is evaluated by a physician who prescribes only if treatment is appropriate.

Storefront-first with a clinical review behind it, and unusually generous on the support side: physician consultation and ongoing review, free priority shipping in discreet packaging, a personalized dosing protocol, monthly check-ins with dose adjustments, and unlimited messaging with the care team are listed as included on every plan card, including the sermorelin card. Delivery is described as roughly 48 hours by priority shipping across all 50 states, with some states requiring a video consultation before a prescription is issued. The identity layer is stronger than most: the founder is named with his specialty and licensure, the site displays a LegitScript seal, a business address in Oakbrook Terrace, Illinois and a phone number are published, and coverage is stated as all 50 states rather than confirmed at intake. At checkout a pending charge is placed but, the site says, not processed until a prescription is approved; once medication ships, all sales are final. What is not disclosed is the pharmacy — medications are described only as coming from FDA-regulated, state-licensed US compounding pharmacies, with no partner named. Pricing presentation is worth reading carefully too. Its hormone-therapy cards carry a first-order-only 50% discount code, and its GLP-1 cards carry a 50%-off-first-month badge. The sermorelin card carries no such badge, showing $149 and $99 against struck-through $299 and $166 figures, but the sermorelin product page states that the pricing shown is introductory and subject to change. Ask what the rate will be after your first months before you commit.

Sermorelin is $149 a month on the one-month plan, billed monthly, and $99 a month on the three-month plan, billed quarterly — $297 a quarter — listed against compare-at figures of $299 and $166. What that buys is stated: the physician consultation and ongoing review, free priority discreet shipping, monthly check-ins and dosage adjustments, and unlimited care-team messaging. Two things to establish before you commit. First, no dose, vial size or injection frequency is published beside the price, so "a month" of sermorelin is undefined in volume terms — that is the variable that actually differs between vendors, and it is the question to ask. Second, the product page describes the pricing shown as introductory and subject to change, so ask what you will pay once the introductory period ends. On the weight-loss side, semaglutide is $299 a month with the first month at $149 and $199 a month on a six-month plan, tirzepatide $399 with the first month at $199 and $265 on six months, and microdose entry tiers sit lower — those are GLP-1 figures and are not a peptide price.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. RestorLife states in its own copy that compounded medications are not FDA-approved as finished products and that its pharmacies are FDA-regulated and state-licensed, but it does not name them, and compounded sterile preparations are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, there is only one peptide here to assess. Sermorelin is a growth-hormone-releasing hormone analog: it acts on the pituitary to release your own growth hormone rather than supplying exogenous hormone, which keeps the somatostatin feedback loop intact and is the meaningful mechanistic difference from injected HGH. That mechanism is real and well characterized. What is thin is the long-term human outcome data — short-term rises in GH and IGF-1 are measurable, and the recovery, sleep and lean-body-composition claims the category is sold on do not rest on controlled outcome trials at that level. The site's framing of sermorelin as a complement to hormone therapy is at least honest about it being an adjunct rather than a headline treatment. Individual results vary.